Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 13 Jan 2020
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
Stephen Padilla, 6 days ago
The Lancet Commission on Hypertension Group has recently released a position statement that contains a list of recommendations for the improvement of accuracy standards for devices that measure blood pressure (BP).

Cyclosporine shows promise in treatment of moderate-to-severe alopecia areata

25 Aug 2019

Treatment with cyclosporine results in improvements, albeit statistically nonsignificant, in the Severity of Alopecia Tool score and eyelash and eyebrow assessment scales among patients with moderate-to-severe alopecia areata (AA), a recent study has shown.

Thirty-two patients were included in the analysis, of whom 16 received cyclosporine and 16 placebo. A greater proportion of participants in the cyclosporine group achieved at least a 50-percent reduction in the Severity of Alopecia Tool score (31.3 percent vs 6.3 percent; p=0.07) and a 1-grade improvement in eyelash (18.8 percent vs 0 percent; p=0.07) and eyebrow (31.3 percent vs 0 percent; p=0.02) scale score compared with those in the placebo group.

“Small sample size and single-institution trial may limit interpretation and generalizability of these results,” the investigators said.

In another study, treatment with oral cyclosporin for moderate-to-severe AA for 3 months resulted in trends for improvement in quality of life across multiple dimensions in both disease-specific and generic measures. [J Dermatolog Treat 2019;doi:10.1080/09546634.2019.1654068]

This double-blind, randomized, placebo-controlled trial was performed to assess the efficacy of cyclosporine compared with placebo in patients aged 18–65 years with moderate-to-severe AA. Participants were randomized 1:1 to receive 3 months of cyclosporine (4 mg/kg/d) or matching placebo.

Blinded assessments included the following: physical examination, blood biochemistry, photography, quality of life measurements, and efficacy evaluation using the Severity of Alopecia Tool score and eyelash and eyebrow assessment scales.

AA is a common autoimmune disease that often results in unpredictable hair loss with substantial psychological burden.

Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 13 Jan 2020
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
Stephen Padilla, 6 days ago
The Lancet Commission on Hypertension Group has recently released a position statement that contains a list of recommendations for the improvement of accuracy standards for devices that measure blood pressure (BP).